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1. Introduction 
Dehydroepiandrosterone (DHEA) is either secreted directly from the adrenal cortex or is 
converted from DHEA sulfate (DHEA-S) in the peripheral organs. DHEA and DHEA-S are 
the most abundant adrenal androgens in blood, however their its physiological roles still 
remain unclear. Some recent studies have shown that DHEA and DHEA-S exert beneficial 
effects on conditions such as diabetes mellitus, atherosclerosis, obesity, tumors and 
osteoporosis (Coleman et al.,1982; Gorden et al.,1988; Cleary,1991). In this chapter, the 
relationships between DHEA or DHEA-S and diabetes mellitus (DM) or impaired glucose 
tolerance (IGT) are described.  
2. Clinical and basic study 
2.1 Clinical study 
Abnormalities of secretion and metabolism of many steroid hormones occur in DM. In 
poorly controlled type 1 DM, serum concentrations of DHEA and DHEA-S decrease 
(Couch,1992) while plasma ACTH and cortisol levels increase in type 2 DM (Hashimoto et 
al.,1993). Low levels of DHEA and DHEA-S in type 2 DM are associated with 
hyperinsulinemia(Hubert et al.,1991; Nesler et al.,1989; Schriock et al.,1988; Smith et 
al.,1987;). We analyzed serum DHEA and DHEA-S levels in poorly controlled type 2 DM. 
2.1.1 Subjects and methods 
The subjects were type 2 diabetic patients seen regularly at the outpatient clinic of Toho 
University Hospital. We chose 130 patients, whose blood glucose control had been poor 
(more than 10% in HbA1c). Their medication was managed by diet only or with 
sulfonylurea, and patients under insulin therapy were excluded. The patient group 
consisted of 74 men and 56 women between the ages of 40-69yr. Age-matched normal 
subjects served as the control group. Informed consent was obtained from each subject 
before the study. 
Blood samples were obtained from patients with type 2 diabetes mellitus and normal 
subjects between 9 and 10 a.m. after an overnight fast. From patients with type 2 diabetes 
mellitus, blood samples were obtained before and 6 months after the treatment. Serum 
levels of DHEA, DHEA-S and immunoreactive insulin (IRI), fasting plasma glucose (FPG) 
and HbA1c were measured. Steroid hormones were determined by the previously reported 
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HPLC/RIA method(Ueshiba et al.,1991) except DHEA-S which was measured using RIA 
kit(Mitsubisi Chemical Co., Tokyo, Japan), FPG by glucose oxidase method, HbA1c by 
HPLC, IRI by commercial kits (Daiichi, Tokyo, Japan). Data are showed as mean ± SD. 
Variables were compared by Bonferroni's analysis and p-values less than 0.05 were 
considered to indicate statistical significance. 
2.1.2 Results 
Serum levels of DHEA and DHEA-S were low in both male and female patients with type 2 
DM across the entire age range studied, compared to the age-matched normal subjects 
(Fig.1). IRI was high in all groups before the treatment (Table1). Following a 6-month 
treatment, FPG and HbA1c improved and IRI decreased in most patients (Table1).  In 
parallel with the improvement of FPG and HbA1c, blood concentrations of DHEA and 
DHEA-S levels increased to within the normal range in all the groups (Fig.1). 
 
 Number FPG(mg/dl) HbA1c(%) IRI(μU/ml) 
Male 40 years 
 Before treatment 
 After treatment 
 Normal 
 
22 
22 
20 
 
183±16 
111±14 
93±7 
 
11.6±1.2 
7.2±0.6 
5.2±0.3 
 
11.8±3.9 
8.7±2.1 
5.9±2.3 
Male 50 years 
 Before treatment 
 After treatment 
 Normal 
 
29 
29 
25 
 
172±18 
106±14 
94±5 
 
11.7±1.2 
6.8±0.6 
5.1±0.3 
 
12.4±3.7 
8.4±1.5 
6.1±2.1 
Male 60 years 
 Before treatment 
 After treatment 
 Normal 
 
23 
23 
20 
 
176±19 
108±14 
90±7 
 
11.4±1.1 
6.7±0.6 
5.2±0.2 
 
13.3±4.1 
8.9±3.4 
5.8±1.8 
Female 40 years 
 Before treatment 
 After treatment 
 Normal 
 
17 
17 
15 
 
172±16 
108±12 
94±7 
 
12.0±1.1 
7.0±0.6 
5.1±0.2 
 
11.9±3.2 
9.3±2.8 
5.4±1.5 
Female 50 years 
 Before treatment 
 After treatment 
 Normal 
 
23 
23 
20 
 
166±16 
112±15 
92±7 
 
11.6±0.8 
7.1±0.4 
5.1±0.3 
 
12.3±3.8 
8.1±2.4 
4.8±1.6 
Female 60 years 
 Before treatment 
 After treatment 
 Normal 
 
16 
16 
15 
 
175±19 
107±9 
93±5 
 
11.9±1.2 
6.8±0.5 
5.3±0.3 
 
11.6±2.8 
7.9±2.7 
4.7±1.8 
Table 1. Clinical characteristics of type 2 diabetic patients before and after treatment and in 
age-matched normal subjects. 
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*P< 0.05 compared with values after treatment and with normal values 
Fig. 1. Serum DHEA and DHEA-S levels in male and female type 2 diabetic patients before 
(stippled bars) and after (hatched bars) treatment and in age-matched normal subjects 
(opena bars). 
2.1.3 Discussion 
In this study we demonstrated that serum DHEA and DHEA-S levels decreased markedly 
with poor control of type 2 DM and increased to age-matched normal values with the 
improvement of FPG and HbA1c after 6 months' treatment with diet and/or sulfonylurea. 
Barrett-Connor showed that DHEA and DHEA-S levels were also low in patients with non-
insulin-dependent diabetes mellitus (Barrett-Connor, 1992), but she did not measure the 
changes of these steroid hormones after treatment.  Markedly reduced levels of DHEA and 
DHEA-S in type 2 DM with poor therapeutic control with slightly increased plasma IRI are 
consistent with an association between DHEA synthesis and/or metabolism and insulin. 
Nestler et al. showed  that insulin reduces serum DHEA and DHEA-S by increasing the 
metabolic clearance rate of DHEA in men or inhibiting their productin (Nestler,1992). The 
metablic clearance rate of DHEA is reported to be increased two- to fivefold in obesity and 
insulin-resistant, hyperinsulinemic state (Nestler,1995). The infusion of a high dose of 
insulin reduces serum DHEA levels suggesting the involvement of the inhibition of adrenal 
17,20lyase activity. The administration of metformin which inhibits hepatic glucose 
production and enhances peripheral tissue sensitivity to insulin, to healthy normal weight 
men and to obese men with hypertension but without diabetes mellitus decreased serum 
insulin levels and increased serum DHEA-S levels in obese men with hypertension and in 
healthy controls (Nestler,1995). However, Yamauchi et al. reported that serum DHEA and 
DHEA-S are low even in patients with impaired glucose tolerance and low insulin response 
(Yamauchi,1996), and therefore the decrease in serum DHEA levels may not exclusively 
arise from the hyperinsulinemic state.  Hyperglycemia may reduce 17,20-lyase activity and 
consequently serum DHEA may decrease. The improvement of plasma glucose control 
parallels the recovery of 17,20-lyase activity.     
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2.2 Basic study 
The guinea pig utilizes a similar mechanism of adrenal steroidogenesis to that of humans. In 
a guinea pig model in which impaired glucose tolerance is induced by streptozotocin (STZ) 
treatment, we measured serum levels of DHEA, DHEA-S and c-peptide to determine if these 
were related to serum glucose levels. 
2.2.1 Materials and methods 
All experiments were performed using Hartley male guinea pigs with a body weight of 500-
600 g. Experimental protocols followed the Principals of Laboratory Animal Care and were 
approved by the Ethics Committee of Toho University School of Medicine. Until 
experiments began, guinea pigs were housed in groups of three in metabolism cages in a 
temperature-controlled room with a 12h light/dark cycle. They had free access to tap water 
and guinea pig chow.   
Under intra-abdominal anaesthesia (pentobarbital sodium 30mg/Kg), streptozotocin (STZ) 
was administrated to 12 guinea pigs intra-abdominally. After 4 weeks, a glucose tolerance 
test (50% glucose, 1g/Kg, intra-abdominal route) was performed. Impaired glucose 
tolerance (IGT) was defined as a blood glucose level of more than 300 mg/dl after 3 hrs. Six 
control guinea pigs had intra-abdominal saline only. 
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Fig. 2. Changes in Concentrations of Serum DHEA 
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Blood samples were taken from intra-orbital vessels after 12 hrs starvation. Serum DHEA, 
DHEA-S, fasting plasma glucose (FPG) and serum c-peptide were measured in each group 
at four time points: before STZ administration; after 4 weeks; after 8 weeks; and after 12 
weeks. Simultaneously glucose tolerance tests were performed. From 15 weeks of STZ 
administration DHEA-S(Mylis) (20mg/Kg) was administrated via the intra-abdominal route 
three times per week in three IGT group guinea pigs and three control group animals. After 
4 weeks, 8 weeks and 12 weeks of DHEA-S administration, blood samples were taken by the 
same method and glucose tolerance tests were also performed.  
Data are expressed as mean±SD. Statistical analysis was performed using ANOVA with 
Bonferroni’s correction. A value of p<0.05 was considered statistically significant. 
2.2.2 Results 
Concentrations of serum DHEA showed no significant change during observation in the 
control group, however there was a tendency towards decrease in the IGT group (Fig. 2). 
Concentrations of serum DHEA-S also had no significant change in the control group. 
However, in the IGT group, concentrations of serum DHEA-S decreased significantly from 
39.0±4.2 μg/dl (before STZ administration) to 27.5±5.0 μg/dl (after 8 weeks)(p<0.05)(Fig. 3). 
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Fig. 3. Changes in Concentrations of Serum DHEA-S 
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Blood glucose levels three hours after DHEA-S administration showed no significant change 
between guinea pigs with DHEA-S and those without DHEA-S in the control group. In the 
IGT group, three hour blood glucose levels had improved from 333.7±24.5 mg/dl (before) to 
190.7±89.8 mg/dl (after 4 weeks) (Fig. 4). However FPG showed no significant change between 
the control group and the IGT group. The result was similar after DHEA-S administration. 
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Fig. 4. Changes in 3 hour blood glucose level 
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Fig. 5. Changes in serum C-peptide after STZ administration 
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Serum c-peptide levels showed no significant change during observation in the control 
group. However in the IGT group, these levels decreased significantly from 1.280±0.144 
ng/ml (before) to 0.965±0.272 ng/ml (after 12 weeks)(Fig. 5 ). Serum c-peptide levels after 
DHEA-S administration were not significantly different between guinea pigs with DHEA-S 
and those without DHEA-S in both the control group and the IGT group. C-peptide levels 
continued to be significantly lower in the IGT group than in the control group (P<0.05) (Fig. 6). 
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Fig. 6. Changes in serum c-peptide after DHEA-S administration 
2.2.3 Discussion 
Coleman et al.(1982). first reported that DHEA had an effect on lowering blood glucose in 
animal experiments. Since this report, there have been many reports that DHEA and DHEA-
S are related to insulin or blood glucose levels. However, their exact role has not been 
determined (Gansler et al.,1985; Farah et al.,1992; Barrett-Connor,1992; Yamaguchi et 
al.,1998). Some of these reports described the use of rats and mice in animal experiments, 
but few studies used guinea pigs which have a similar mechanism of adrenal 
steroidogenesis to that of humans (Strott et al.,1981; Hyatt et al.,1983) In our guinea pig 
models in which impaired glucose tolerance is induced by STZ treatment , serum levels of 
DHEA and DHEA-S were decreased. We measured serum c-peptide instead of serum 
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insulin because there were no reports of serum insulin measurements in guinea pigs 
(Massey&Smyth,1975; Rosenzweig et al.,1980; Gracia-Webb et al.,1983; Schlosser et al.,1987). 
Guinea pigs in the IGT group showed a significant decrease in serum c-peptide levels and it 
was speculated that this was not hyper-insulinemia. In IGT group guinea pigs, blood 
glucose levels improved after DHEA-S administration, however serum c-peptide levels 
were still significantly decreased. There was no correlation between serum c-peptide levels 
and DHEA or DHEA-S levels. In the STZ-induced model of diabetes, adult rats ranged from 
mild type 2 diabetes to type 1 diabetes depending upon STZ dose (Ho RS et al.,1988).  In this 
experiment, fasting blood glucose levels in STZ-administered guinea pigs were not 
significantly different from those in control group. However, serum c-peptide levels were 
decreased and this state was thought to be approaching type 1 diabetes.  
Similar to clinical data, it was thought that hyperglycemia itself suppressed DHEA and 
DHEA-S after prolonged hyperglycemia independent of serum insulin levels in the absence 
of hyperinsulinemia. In IGT group guinea pigs, serum c-peptide was still decreased after 
DHEA-S administration, however blood glucose levels improved significantly. It was 
thought that DHEA-S itself was involved in this improvement of blood glucose levels. In the 
hyperglycemic state in humans, the mechanism of decrease of DHEA and DHEA-S levels is 
not still clear. It has been reported that DHEA levels are low in situations of life-threatening 
stress(Parker et al., 1985; Wade et al.,1988).  Long duration hyperglycemia in this experiment 
is a form of excessive stress. It was speculated that histological changes in the adrenal gland 
may occur. The zona fasciculata which secretes cortisol necessary to maintain life may 
become enlarged and the zona reticularis which secretes DHEA and DHEA-S may shrink. In 
addition to reports of the mechanism of the improvement of impaired glucose tolerance by 
DHEA and DHEA-S, further studies reported a number of other effects. These included 
acceleration of glucose uptake in cells, increasing sensitivity in insulin sensitive tissue and 
suppressing the activities of G6Pase and FBPase, the enzymes of glyconeogenesis in the 
liver(McIntosh & Berdanier,1991; Nakashima et al.,1995)  However, many points remained 
unclear. 
3. Conclusion 
These experiments suggest that the relationship between blood glucose levels and DHEA or 
DHEA-S is close. It is therefore possible that DHEA-S may become a therapeutic agent for 
diabetes mellitus in the future.   
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